BACKGROUND: Infection with high-risk human papillomavirus (HPV)types has been recognized as a causal factor for the development of cervical cancer and a number of other malignancies. Today, vaccines against HPV, highly effective in the prevention of persistent infection and precancerous lesions, are available for the routine clinical practice. OBJECTIVES: The data on the prevalence and type-specific HPV distribution in the population of each country are crucial for the surveillance of HPV type-specific prevalence at the onset of vaccination against HPV. METHODS: Women attending a preventive gynecological examination who had no history of abnormal cytological finding and/or surgery for cervical lesions were enrolled. All samples were tested for the presence of HPV by High-Risk Hybrid Capture 2 (HR HC2) and by a modified PCR-reverse line blot assay with broad spectrum primers (BS-RLB). RESULTS: Cervical smears of 1393 women were analyzed. In 6.5% of women, atypical cytological findings were detected. Altogether, 28.3% (394/1393) of women were positive for any HPV type by BS-RLB, 18.2% (254/1393) by HR HC2, and 22.3% (310/1393) by BS-RLB for HR HPV types. In women with atypical findings the prevalence for HR and any HPV types were significantly higher than in women with normal cytological findings. Overall, 36 different HPV types were detected, with HPV 16 being the most prevalent (4.8%). HPV positivity decreased with age; the highest prevalence was 31.5% in the age group 21-25 years. CONCLUSIONS: Our study subjects represent the real screening population. HPV prevalence in this population in the Czech Republic is higher than in other countries of Eastern Europe. Also the spectrum of the most prevalent HPV types differs from those reported by others but HPV 16 is, concordantly, the most prevalent type. Country-specific HPV type-specific prevalences provide baseline information which will enable to measure the impact of HPV vaccination in the future.

Department of Experimental Virology Institute of Hematology and Blood Transfusion Prague Czech Republic

Zobrazit více v PubMed

Walboomers JM, Meijer CJ (1997) Do HPV-negative cervical carcinomas exist? J Pathol 181: 253-254. doi:10.1002/(SICI)1096-9896(199703)181:3. PubMed: 9155707. PubMed DOI

zur Hausen H (1996) Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta 1288: F55-F78. PubMed: 8876633. PubMed

Gillison ML, Shah KV (2003) Role of mucosal human papillomavirus in nongenital cancers chapter 57 J Natl Cancer Inst Monogr: 65. PubMed: 12807947 PubMed

de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L et al. (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7: 453-459. doi:10.1016/S1473-3099(07)70158-5. PubMed: 17597569. PubMed DOI

Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX et al. (2010) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202: 1789-1799. doi:10.1086/657321. PubMed: 21067372. PubMed DOI

Tachezy R, Hamsíková E, Hájek T, Mikysková I, Smahel M et al. (1999) Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles. J Med Virol 58: 378-386. doi:10.1002/(SICI)1096-9071(199908)58:4. PubMed: 10421405. PubMed DOI

Tachezy R, Davies P, Arbyn M, Rob L, Lazdane G et al. (2008) Consensus recommendations for cervical cancer prevention in the Czech Republic: a report of the International Conference on Human Papillomavirus in Human Pathology (Prague, 1-3 May 2008). J Med Screen 15: 207-210. doi:10.1258/jms.2008.008057. PubMed: 19106262. PubMed DOI

Ministry of Public Health; Bulletin of . (2004) 7: 7-11.

Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M et al. (2012) Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30 Suppl 5: F88-F99. doi:10.1016/j.vaccine.2012.06.095. PubMed: 23199969. PubMed DOI

Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Rozendaal L et al. (2012) HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer 106: 975-981. doi:10.1038/bjc.2011.581. PubMed: 22251922. PubMed DOI PMC

Harper DM (2009) Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 8: 1663-1679. doi:10.1586/erv.09.123. PubMed: 19943762. PubMed DOI

Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D et al. (2002) The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287: 2114-2119. doi:10.1001/jama.287.16.2114. PubMed: 11966386. PubMed DOI

Schmitt M, Dondog B, Waterboer T, Pawlita M (2008) Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol 46: 1050-1059. doi:10.1128/JCM.02227-07. PubMed: 18199790. PubMed DOI PMC

van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ et al. (2002) GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 40: 779-787. doi:10.1128/JCM.40.3.779-787.2002. PubMed: 11880393. PubMed DOI PMC

Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M et al. (2006) Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 44: 504-512. doi:10.1128/JCM.44.2.504-512.2006. PubMed: 16455905. PubMed DOI PMC

Tachezy R, Mikysková I, Ludvíková V, Rob L, Kucera T et al. (2006) Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies. Eur J Clin Microbiol Infect Dis 25: 492-500. doi:10.1007/s10096-006-0172-5. PubMed: 16896828. PubMed DOI

Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA et al. (2009) Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 125: 2151-2158. doi:10.1002/ijc.24528. PubMed: 19585494. PubMed DOI PMC

Bernard HU, Burk RD, Chen Z, Van DK, Hausen H et al. (2010) Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401: 70-79. doi:10.1016/j.virol.2010.02.002. PubMed: 20206957. PubMed DOI PMC

IARC Monograph Working Group (2007). IARC Monogr Eval Carcinog Risks Hum. 90: 1–636. PubMed: 18354839 PubMed PMC

Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527. doi:10.1056/NEJMoa021641. PubMed: 12571259. PubMed DOI

Eklund C, Zhou T, Dillner J (2010) Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 48: 4147-4155. doi:10.1128/JCM.00918-10. PubMed: 20844222. PubMed DOI PMC

Eklund C, Forslund O, Wallin KL, Zhou T, Dillner J (2012) The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol 50: 2289-2298. doi:10.1128/JCM.00840-12. PubMed: 22535980. PubMed DOI PMC

Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ et al. (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366: 991-998. doi:10.1016/S0140-6736(05)67069-9. PubMed: 16168781. PubMed DOI

Učakar V, Poljak M, Klavs I (2012) Pre-vaccination prevalence and distribution of high-risk human papillomavirus (HPV) types in Slovenian women: a cervical cancer screening based study. Vaccine 30: 116-120. doi:10.1016/j.vaccine.2011.10.066. PubMed: 22080175. PubMed DOI

Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J et al. (2013) Prevalence and viral load of 51 genital human papillomavirus types and three subtypes. Int J Cancer 132: 2395-2403. doi:10.1002/ijc.27891. PubMed: 23034864. PubMed DOI

Kulmala SM, Shabalova IP, Petrovitchev N, Syrjänen KJ, Gyllensten UB et al. (2007) Prevalence of the most common high-risk HPV genotypes among women in three new independent states of the former Soviet Union. J Med Virol 79: 771-781. doi:10.1002/jmv.20839. PubMed: 17457909. PubMed DOI

Bardin A, Vaccarella S, Clifford GM, Lissowska J, Rekosz M et al. (2008) Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Eur J Cancer 44: 557-564. doi:10.1016/j.ejca.2007.12.001. PubMed: 18191395. PubMed DOI

Tachezy R, Smahelova J, Salakova M, Arbyn M, Rob L et al. (2011) Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPV. PLOS ONE 6: e21913. doi:10.1371/journal.pone.0021913. PubMed: 21765924. PubMed DOI PMC

Burden of HPV-induced diseases and cost effectiveness of catch-up vaccination in Czech Republic: a model-based study

Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis: A Nonrandomized Clinical Trial

Prevalence and genotype distribution of human papillomavirus in Czech non-vaccinated heterosexual couples

Detailed Characteristics of Tonsillar Tumors with Extrachromosomal or Integrated Form of Human Papillomavirus

Prevalence of human papillomavirus infection in oocyte donors and women treated for infertility: An observational laboratory-based study

Comparison of the miRNA profiles in HPV-positive and HPV-negative tonsillar tumors and a model system of human keratinocyte clones